FDA approves Alkermes ARISTADA treatment for schizophrenia
Alkermes announced that the FDA has approved two-month ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is now FDA-approved in four doses and three dosing duration options (441mg, 662mg or 882mg once monthly, 882mg once every six weeks and 1064mg once every two months) and can be initiated at any dose or interval, offering an unprecedented range of flexibility to patients and healthcare providers. The new two-month dose is expected to be available in mid-June.
“We designed ARISTADA to offer flexibility to meet the real-world needs of patients suffering from schizophrenia and the healthcare professionals providing their care. As the first and only long-acting atypical antipsychotic approved in three dosing durations and with the ability to initiate treatment at any dose or duration, ARISTADA provides a range of options to help clinicians tailor treatment to the individual needs of their patients,” said Elliot Ehrich, M.D., executive vice president, Research and Development of Alkermes. “Building on nearly two decades of experience developing innovative medicines for chronic and serious CNS diseases, we are dedicated to helping improve the lives of patients with treatment options that are well-suited for use in today’s complex treatment system.”
Treatment adherence for patients on daily therapy for chronic diseases is a known challenge for patients, and schizophrenia may make this challenge even greater. Long-acting injectable medications, like ARISTADA, eliminate the burden of taking an oral antipsychotic medicine on a daily basis. The newly approved two-month ARISTADA gives people living with schizophrenia an option to treat their symptoms with only six injections per year.
“Transitioning patients with schizophrenia from inpatient care to outpatient settings can be challenging. The availability of an antipsychotic that can be initiated prior to hospital discharge and provide therapeutic levels of medication for two months will be a welcome new treatment option for healthcare providers, caregivers and patients,” said Joseph McEvoy, M.D., I. Clark Case Distinguished Chair in Psychotic Disorders at Augusta University and Professor Emeritus of Psychiatry and Behavioral Health at Duke University Medical Center. “The clinical community is increasingly using long-acting atypical antipsychotic medications earlier in the treatment paradigm as recognition grows of the benefits of less frequent dosing and the resulting ability to focus on other important treatment goals for patients.”